Literature DB >> 23921745

Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma.

Guy G Brusselle1, Tania Maes, Ken R Bracke.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23921745     DOI： 10.1038/nm.3300

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  12 in total

Review 1.  Asthma phenotypes: the evolution from clinical to molecular approaches.

Authors:  Sally E Wenzel
Journal:  Nat Med       Date:  2012-05-04       Impact factor: 53.440

2.  Changes in sputum eosinophils predict loss of asthma control.

Authors:  A Jatakanon; S Lim; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

Review 3.  The role of dendritic and epithelial cells as master regulators of allergic airway inflammation.

Authors:  Bart N Lambrecht; Hamida Hammad
Journal:  Lancet       Date:  2010-09-04       Impact factor: 79.321

4.  Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161.

Authors:  Jenny M Mjösberg; Sara Trifari; Natasha K Crellin; Charlotte P Peters; Cornelis M van Drunen; Berber Piet; Wytske J Fokkens; Tom Cupedo; Hergen Spits
Journal:  Nat Immunol       Date:  2011-09-11       Impact factor: 25.606

5.  Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma.

Authors:  Cindy Barnig; Manuela Cernadas; Stefanie Dutile; Xiaoli Liu; Mark A Perrella; Shamsah Kazani; Michael E Wechsler; Elliot Israel; Bruce D Levy
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

6.  Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity.

Authors:  Hye Young Kim; Ya-Jen Chang; Srividya Subramanian; Hyun-Hee Lee; Lee A Albacker; Ponpan Matangkasombut; Paul B Savage; Andrew N J McKenzie; Dirk E Smith; James B Rottman; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  J Allergy Clin Immunol       Date:  2011-11-25       Impact factor: 10.793

7.  A large-scale, consortium-based genomewide association study of asthma.

Authors:  Miriam F Moffatt; Ivo G Gut; Florence Demenais; David P Strachan; Emmanuelle Bouzigon; Simon Heath; Erika von Mutius; Martin Farrall; Mark Lathrop; William O C M Cookson
Journal:  N Engl J Med       Date:  2010-09-23       Impact factor: 91.245

8.  IL-33-responsive lineage- CD25+ CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs.

Authors:  Kathleen R Bartemes; Koji Iijima; Takao Kobayashi; Gail M Kephart; Andrew N McKenzie; Hirohito Kita
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

9.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Authors:  Ian D Pavord; Stephanie Korn; Peter Howarth; Eugene R Bleecker; Roland Buhl; Oliver N Keene; Hector Ortega; Pascal Chanez
Journal:  Lancet       Date:  2012-08-18       Impact factor: 79.321

Review 10.  Innate lymphoid cells--a proposal for uniform nomenclature.

Authors:  Hergen Spits; David Artis; Marco Colonna; Andreas Diefenbach; James P Di Santo; Gerard Eberl; Shigeo Koyasu; Richard M Locksley; Andrew N J McKenzie; Reina E Mebius; Fiona Powrie; Eric Vivier
Journal:  Nat Rev Immunol       Date:  2013-02       Impact factor: 53.106
View more
  81 in total

Review 1.  Update on reslizumab for eosinophilic asthma.

Authors:  Juan Carlos Cardet; Elliot Israel
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

Review 2.  Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects.

Authors:  E W de Roos; J C C M In 't Veen; G-J Braunstahl; L Lahousse; G G O Brusselle
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

3.  Priming with high and low respiratory allergen dose induces differential CD4+ T helper type 2 cells and IgE/IgG1 antibody responses in mice.

Authors:  Kazuki Furuhashi; Yen L Chua; Kenneth H S Wong; Qian Zhou; Debbie C P Lee; Ka H Liong; Guo H Teo; Paul E Hutchinson; David M Kemeny
Journal:  Immunology       Date:  2017-04-03       Impact factor: 7.397

4.  The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children.

Authors:  Mohamed S Al-Moamary; Sami A Alhaider; Abdullah A Alangari; Mohammed O Al Ghobain; Mohammed O Zeitouni; Majdy M Idrees; Abdullah F Alanazi; Adel S Al-Harbi; Abdullah A Yousef; Hassan S Alorainy; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2019 Jan-Mar       Impact factor: 2.219

5.  Emergence of Biomolecular Pathways to Define Novel Asthma Phenotypes. Type-2 Immunity and Beyond.

Authors:  Sally E Wenzel
Journal:  Am J Respir Cell Mol Biol       Date:  2016-07       Impact factor: 6.914

Review 6.  In situ hematopoiesis: a regulator of TH2 cytokine-mediated immunity and inflammation at mucosal surfaces.

Authors:  C C K Hui; K M McNagny; J A Denburg; M C Siracusa
Journal:  Mucosal Immunol       Date:  2015-03-18       Impact factor: 7.313

Review 7.  Biologics in asthma--the next step toward personalized treatment.

Authors:  Jared Darveaux; William W Busse
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

Review 8.  Synergy of Interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases.

Authors:  Hemanth Kumar Kandikattu; Sathisha Upparahalli Venkateshaiah; Anil Mishra
Journal:  Cytokine Growth Factor Rev       Date:  2019-05-10       Impact factor: 7.638

Review 9.  Eosinophilic and Noneosinophilic Asthma.

Authors:  Tara F Carr; Amir A Zeki; Monica Kraft
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

10.  Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.

Authors:  Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.